These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26496700)

  • 1. Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma.
    Slemmons KK; Crose LE; Rudzinski E; Bentley RC; Linardic CM
    PLoS One; 2015; 10(10):e0140781. PubMed ID: 26496700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
    Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
    J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.
    Slemmons KK; Crose LES; Riedel S; Sushnitha M; Belyea B; Linardic CM
    Mol Cancer Res; 2017 Dec; 15(12):1777-1791. PubMed ID: 28923841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
    Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
    Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
    Mohamed AD; Shah N; Hettmer S; Vargesson N; Wackerhage H
    Sci Rep; 2018 Oct; 8(1):15674. PubMed ID: 30353028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence.
    Li JJ; Kovach AR; DeMonia M; Slemmons KK; Oristian KM; Chen C; Linardic CM
    Sci Rep; 2021 Aug; 11(1):16505. PubMed ID: 34389744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.
    Schaaf G; Hamdi M; Zwijnenburg D; Lakeman A; Geerts D; Versteeg R; Kool M
    Cancer Res; 2010 Jan; 70(2):762-71. PubMed ID: 20068162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Value of YAP Staining in Rhabdomyosarcoma.
    Ahmed AA; Habeebu SS; Sherman AK; Ye SQ; Wood N; Chastain KM; Tsokos MG
    J Histochem Cytochem; 2018 Aug; 66(8):577-584. PubMed ID: 29596030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
    Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
    Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
    Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
    Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
    Belyea BC; Naini S; Bentley RC; Linardic CM
    Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma.
    Slemmons KK; Yeung C; Baumgart JT; Juarez JOM; McCalla A; Helman LJ
    Cancer Res; 2020 Jul; 80(14):3046-3056. PubMed ID: 32354737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis.
    Huang HJ; Liu J; Hua H; Li SE; Zhao J; Yue S; Yu TT; Jin YC; Cheng SY
    Oncotarget; 2014 Apr; 5(8):2161-75. PubMed ID: 24811402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and targeting of a HES1-YAP1-CDKN1C functional interaction in fusion-negative rhabdomyosarcoma.
    Kovach AR; Oristian KM; Kirsch DG; Bentley RC; Cheng C; Chen X; Chen PH; Chi JA; Linardic CM
    Mol Oncol; 2022 Oct; 16(20):3587-3605. PubMed ID: 36037042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP promotes myogenic differentiation
    Chen TH; Chen CY; Wen HC; Chang CC; Wang HD; Chuu CP; Chang CH
    FASEB J; 2017 Jul; 31(7):2963-2972. PubMed ID: 28356344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
    Raimondi L; Ciarapica R; De Salvo M; Verginelli F; Gueguen M; Martini C; De Sio L; Cortese G; Locatelli M; Dang TP; Carlesso N; Miele L; Stifani S; Limon I; Locatelli F; Rota R
    Cell Death Differ; 2012 May; 19(5):871-81. PubMed ID: 22117196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral small T oncoproteins transform cells by alleviating hippo-pathway-mediated inhibition of the YAP proto-oncogene.
    Nguyen HT; Hong X; Tan S; Chen Q; Chan L; Fivaz M; Cohen SM; Voorhoeve PM
    Cell Rep; 2014 Aug; 8(3):707-13. PubMed ID: 25088426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.
    Yang C; Tan J; Zhu J; Wang S; Wei G
    Oncotarget; 2017 Jun; 8(23):37154-37163. PubMed ID: 28415761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis.
    Chen R; Zhu S; Fan XG; Wang H; Lotze MT; Zeh HJ; Billiar TR; Kang R; Tang D
    Hepatology; 2018 May; 67(5):1823-1841. PubMed ID: 29149457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
    Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
    Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.